Clinical experiences in an open and a double-blind trial.

Abstract

A total of sixty patients were trated with bromperidol first in open conditions (20 patients), then on a double blind basis (40 patients) with haloperidol as the reference substance. The open study lasted for four weeks; the drug was administrated in the form of 1 mg tablets. The daily dose (initial dose: 1 mg; mean dose at the end of the trial: 4.47 mg) was always administered in one single dose. Nineteen patients finished the trial, and in 18 cases the therapeutic result was considered very good to good. These results were confirmed by statistical analysis. Nine patients exhibited mild to moderate extrapyramidal concomitant symptoms; no other side effects were observed. The results of detailed laboratory tests and evaluations of various quantitative and qualitative tolerability parameters were not indicative of toxic effects. In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group. Certain clues, including the onset of action, seem to be indicative of the superiority of bromperidol. No differences were observed with respect to side effects and general tolerability.

• Authors: W Pöldinger
• Journal: Acta psychiatrica Belgica (Acta Psychiatr Belg) 1978 Jan-Feb Vol. 78 Issue 1 Pg. 96-101 ISSN: 0300-8967 [Print] Belgium
• PMID: 347884 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Haloperidol

Topics

• Clinical Trials as Topic
• Double-Blind Method
• Drug Evaluation
• Drug Tolerance
• Female
• Haloperidol (adverse effects, analogs & derivatives, therapeutic use)
• Humans
• Male
• Middle Aged
• Parkinson Disease, Secondary (chemically induced)
• Schizophrenia (drug therapy)